患者衍生性质瘤细胞系的多组和药理学表征
Min Wu1,2,3,4,5, Tingting Wang1,6,7, Nan Ji8,9
1Chinese Institute for Brain Research, Beijing, Research Unit of Medical Neurobiology, Chinese Academy of Medical Sciences, Beijing, China.
Nature communications
|August 7, 2024
概括
这项研究描述了50个来自患者的质瘤细胞系,确定了三种亚型 (介质细胞,脑前神经,氧化酸化),具有明显的药物敏感性和瘤形成能力. 长通道细胞的无血清培养揭示了MYC/MYCN放大,这是临床转化的一个关键问题.
科学领域:
- 神经瘤学神经瘤学
- 基因组学就是基因组学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 质母细胞瘤 (GBM) 是一种侵略性的,无法治愈的脑瘤.
- 初级GBM培养对于药物查至关重要,但缺乏全面的表征.
- 患者衍生性质瘤细胞 (PDGC) 线为GBM研究提供了一个更相关的模型.
研究的目的:
- 在基因组和药理学上对50个PDGC系进行鉴定.
- 识别PDGC中的分子亚型及其药物反应概况.
- 评估不同PDGC亚型的体内瘤形成能力,并评估培养系统的文物.
主要方法:
- 整个基因组的测序.
- 有关RNA测序的RNA测序
- 药物反应查对药物的反应查.
- 在免疫缺陷小鼠的内移植.
主要成果:
- 确定了三种分子亚型:介酶 (MES),前神经 (PN) 和氧化酸化 (OXPHOS).
- PN PDGCs对氨酸激酶抑制剂表现出敏感性;OXPHOS PDGCs对HDAC,OXPHOS和HMG-CoA减少酶抑制剂作出反应.
- PN和OXPHOS PDGCs在体内形成瘤,而大多数MES PDGCs没有.
- 无血清培养的PDGCs,特别是长通道的PDGCs,表现出MYC/MYCN放大,这是患者中罕见的发现.
结论:
- 这项研究为GBM研究和临床翻译提供了宝贵的资源.
- PDGC亚型表现出明显的药物敏感性和体内行为.
- 无血清培养方法,特别是长途PDGCs,引入遗传变化 (MYC/MYCN放大),可能会混结果并阻碍临床适用性.
相关概念视频
Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


